Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Merrill

Showing results (231-240 of 414) with videos related to

Pageof 42
Sort By:
Scientific Reports|June 15, 2019
Immunologic findings precede rapid lupus flare after transient steroid therapyRufei Lu, Joel M Guthridge, Hua Chen, et al.
Clinical and Experimental Rheumatology|July 13, 2018
Antibodies to periodontogenic bacteria are associated with higher disease activity in lupus patientsHarini Bagavant, Micah L Dunkleberger, Nina Wolska, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 4, 2017
The Biomarkers of Lupus Disease Study: A Bold Approach May Mitigate Interference of Background Immunosuppressants in Clinical TrialsJoan T Merrill, Fred Immermann, Maryann Whitley, et al.
Atmospheric Environment (Oxford, England : 1994)|May 28, 2020
Quantifying stratosphere-troposphere transport of ozone using balloon-borne ozonesondes, radar windprofilers and trajectory modelsD W Tarasick, T K Carey-Smith, W K Hocking, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 10, 2016
Autoantibody-Positive Healthy Individuals Display Unique Immune Profiles That May Regulate AutoimmunitySamantha Slight-Webb, Rufei Lu, Lauren L Ritterhouse, et al.
Ocular Immunology and Inflammation|March 14, 2012
Hypotony in patients with uveitis: The Multicenter Uveitis Steroid Treatment (MUST) TrialH Nida Sen, Lea T Drye, Debra A Goldstein, et al.
The Journal of Rheumatology|December 17, 2017
Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid ArthritisAlan Kivitz, Ewa Olech, Michael A Borofsky, et al.
Rheumatology (Oxford, England)|October 19, 2017
Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder indexKenneth C Kalunian, Murray B Urowitz, David Isenberg, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 12, 2022
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled TrialEric Morand, Marilyn Pike, Joan T Merrill, et al.
Ophthalmology|June 23, 2020
Efficacy and Safety of Intravitreal Sirolimus for Noninfectious Uveitis of the Posterior Segment: Results from the Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) ProgramPauline T Merrill, W Lloyd Clark, Alay S Banker, et al.
Pageof 42

Showing results (231-240 of 414) with videos related to

Sort By:
Pageof 42
Scientific Reports|June 15, 2019
Immunologic findings precede rapid lupus flare after transient steroid therapyRufei Lu, Joel M Guthridge, Hua Chen, et al.
Clinical and Experimental Rheumatology|July 13, 2018
Antibodies to periodontogenic bacteria are associated with higher disease activity in lupus patientsHarini Bagavant, Micah L Dunkleberger, Nina Wolska, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 4, 2017
The Biomarkers of Lupus Disease Study: A Bold Approach May Mitigate Interference of Background Immunosuppressants in Clinical TrialsJoan T Merrill, Fred Immermann, Maryann Whitley, et al.
Atmospheric Environment (Oxford, England : 1994)|May 28, 2020
Quantifying stratosphere-troposphere transport of ozone using balloon-borne ozonesondes, radar windprofilers and trajectory modelsD W Tarasick, T K Carey-Smith, W K Hocking, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 10, 2016
Autoantibody-Positive Healthy Individuals Display Unique Immune Profiles That May Regulate AutoimmunitySamantha Slight-Webb, Rufei Lu, Lauren L Ritterhouse, et al.
Ocular Immunology and Inflammation|March 14, 2012
Hypotony in patients with uveitis: The Multicenter Uveitis Steroid Treatment (MUST) TrialH Nida Sen, Lea T Drye, Debra A Goldstein, et al.
The Journal of Rheumatology|December 17, 2017
Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid ArthritisAlan Kivitz, Ewa Olech, Michael A Borofsky, et al.
Rheumatology (Oxford, England)|October 19, 2017
Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder indexKenneth C Kalunian, Murray B Urowitz, David Isenberg, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 12, 2022
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled TrialEric Morand, Marilyn Pike, Joan T Merrill, et al.
Ophthalmology|June 23, 2020
Efficacy and Safety of Intravitreal Sirolimus for Noninfectious Uveitis of the Posterior Segment: Results from the Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) ProgramPauline T Merrill, W Lloyd Clark, Alay S Banker, et al.
Pageof 42